WO2022184068A8 - 抗tigit抗体在治疗肿瘤或癌症中的应用 - Google Patents

抗tigit抗体在治疗肿瘤或癌症中的应用 Download PDF

Info

Publication number
WO2022184068A8
WO2022184068A8 PCT/CN2022/078683 CN2022078683W WO2022184068A8 WO 2022184068 A8 WO2022184068 A8 WO 2022184068A8 CN 2022078683 W CN2022078683 W CN 2022078683W WO 2022184068 A8 WO2022184068 A8 WO 2022184068A8
Authority
WO
WIPO (PCT)
Prior art keywords
tigit antibody
cancers
treating tumors
application
antigen
Prior art date
Application number
PCT/CN2022/078683
Other languages
English (en)
French (fr)
Other versions
WO2022184068A9 (zh
WO2022184068A1 (zh
Inventor
黄俊杰
徐振前
黄贤明
俞金泉
李胜峰
Original Assignee
百奥泰生物制药股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 百奥泰生物制药股份有限公司 filed Critical 百奥泰生物制药股份有限公司
Publication of WO2022184068A1 publication Critical patent/WO2022184068A1/zh
Publication of WO2022184068A9 publication Critical patent/WO2022184068A9/zh
Publication of WO2022184068A8 publication Critical patent/WO2022184068A8/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Abstract

本发明提供抗TIGIT抗体或抗原结合片段在制备治疗肿瘤或癌症的药物中的用途。本发明还提供一种试剂盒，包含抗TIGIT抗体或抗原结合片段和用于指导有需要患者给药抗TIGIT抗体或抗原结合片段的说明书。
PCT/CN2022/078683 2021-03-02 2022-03-01 抗tigit抗体在治疗肿瘤或癌症中的应用 WO2022184068A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CNPCT/CN2021/078724 2021-03-02
CN2021078724 2021-03-02

Publications (3)

Publication Number Publication Date
WO2022184068A1 WO2022184068A1 (zh) 2022-09-09
WO2022184068A9 WO2022184068A9 (zh) 2022-10-06
WO2022184068A8 true WO2022184068A8 (zh) 2023-11-02

Family

ID=83024253

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2022/078683 WO2022184068A1 (zh) 2021-03-02 2022-03-01 抗tigit抗体在治疗肿瘤或癌症中的应用

Country Status (2)

Country Link
CN (1) CN114989300A (zh)
WO (1) WO2022184068A1 (zh)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3664B1 (ar) * 2014-08-19 2020-08-27 Merck Sharp & Dohme أجسام مضادة لـ tigit
DK3347379T5 (da) * 2016-08-17 2020-06-15 Compugen Ltd Anti-tigit-antistoffer, anti-pvrig-antistoffer og kombinationer deraf
EP3484925B1 (en) * 2017-07-27 2020-05-27 iTeos Therapeutics SA Anti-tigit antibodies
MX2020008795A (es) * 2018-02-28 2020-10-08 Yuhan Corp Anti cuerpos anti tigit y usos de los mismos.
CN109734806B (zh) * 2019-03-15 2022-07-01 安徽安科生物工程（集团）股份有限公司 一种全人源抗huTIGIT单克隆抗体及其应用

Also Published As

Publication number Publication date
WO2022184068A9 (zh) 2022-10-06
WO2022184068A1 (zh) 2022-09-09
CN114989300A (zh) 2022-09-02

Similar Documents

Publication Publication Date Title
MX2020008882A (es) Dosificación para tratamiento con anticuerpos antagonistas anti-tigit y anti-pd-l1.
PH12019502545A1 (en) Anti-cdh6 antibody and anti-cdh6 antibody-drug conjugate
AU2018263862A1 (en) Stable formulations of programmed death receptor 1 (PD-1) antibodies and methods of use thereof
MX2022013163A (es) Anticuerpo contra nectin-4 y aplicacion del mismo.
CA3055791A1 (en) Treatment methods
MX2021009239A (es) Tratamiento contra el cáncer con inmunoconjugados de anticuerpos ror1.
MX2022002592A (es) Conjugado de anticuerpo-farmaco que comprende un anticuerpo contra el gen del receptor huerfano 1 similar a tirosina cinasa receptora (ror1) humano y uso para el mismo.
ZA201907225B (en) Treatment of her2 positive cancers
CR20230128A (es) Anticuerpo anti-nectina-4, conjugado que lo incluye y aplicación de los mismos
MX2021007350A (es) Terapia combinada de cd70 y venetoclax, un inhibidor de bcl-2, para tratar la leucemia mieloide aguda.
Kalemkerian et al. Molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: American Society of Clinical Oncology Endorsement Summary of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Clinical Practice Guideline Update
WO2019234241A8 (en) ANTI-oxMIF/ANTI-CD3 ANTIBODY FOR CANCER TREATMENT
WO2020225805A3 (en) Precursor tri-specific antibody constructs and methods of use thereof
MX2022001841A (es) Anticuerpos contra ilt2 y uso de los mismos.
BR112019023909A2 (pt) método para tratamento de um paciente com câncer de ovário, câncer peritoneal ou câncer de trompa de falópio.
MX2020006171A (es) Terapia de combinacion con anticuerpos anti interleucina-8 (il-8) y anticuerpos anti receptor de muerte programada (pd-1) para tratar cancer.
WO2020132658A3 (en) Tubulysins and protein-tubulysin conjugates
MX2021010116A (es) Anticuerpo anti-pd-l1 y uso de este.
EP3978078A4 (en) COMPLEX, MEDICINE, THERAPEUTIC AGENT FOR CANCER, KIT AND CONJUGATE
AU2021339851A8 (en) Method of treating amyloidosis
WO2021062085A8 (en) Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
WO2022034524A3 (en) Antibodies against ilt2 and use thereof
WO2020176748A8 (en) Dosing for treatment with anti-tigit and anti-cd20 or anti-cd38 antibodies
WO2022184068A8 (zh) 抗tigit抗体在治疗肿瘤或癌症中的应用
EA202191165A1 (ru) Элацестрант в комбинации с абемациклибом у женщин с раком молочной железы

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22762532

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 22762532

Country of ref document: EP

Kind code of ref document: A1